locally advanced or metastatic nsclc

egfr mutation (l858r and /or ex19del)

cmet amplification by fish (gcn ≥ 6),

acquired resistance to egfr tki (1st or 2nd génération)

ecog performance status (ps) ≤ 1.

prior treatment with 3rd generation tki

phaseii : prior treatment with any of the following agents:

crizotinib, or any other cmet inhibitor or hgf-targeting inhibitor.

concomitant egfr tki and platinum based chemotherapy as first line regimen.

platinum-based chemotherapy as first line treatment